Skip to main content
OpenTrials

Clinical trial condition

Refractory Multiple Myeloma

Explore clinical trials studying Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

155 public trials 23 recruiting studies
Refine in advanced search Browse all conditions

Refractory Multiple Myeloma trial results

Completed

A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases

NCT05742217

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • A.O.U. - Ospedali Riuniti di Ancona Torrette, Aviano, Italy
  • A.O.U. Policlinico S.Orsola Malpighi Bologna, BO, Italy
  • "IRCCS "" Casa Sollievo della Sofferenza""tOpera di San Pio da Pietrelcina U.O.C di Ematologia" San Giovanni Rotondo, Foggia, Italy
  • AOU Policlinico Umberto I Rome, Lazio, Italy
View all 20 locations
View Trial Details
Completed

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

NCT04083534

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Regeneron Study Site Indianapolis, Indiana, United States
  • Regeneron Study Site Ann Arbor, Michigan, United States
  • Regeneron Study Site Rochester, Minnesota, United States
  • Regeneron Study Site New York, United States
View Trial Details
Completed

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT03702725

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Loyola University Medical Center Maywood, Illinois, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Wake Forest Baptist Comprehensive Cancer Center Winston-Salem, North Carolina, United States
  • The Ohio State University Wexner Medical Center/James Cancer Hospital Columbus, Ohio, United States
View Trial Details
Completed

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

NCT05228470

Conditions
BCMA, BCMA-CD3 Bispecific, Bispecific, +23 more
Locations
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Guangdong Provincial People's Hospital Guangzhou, Guangdong, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View all 15 locations
View Trial Details

Related conditions